Asthma Reporting with Anti-TNFalpha Drugs used in Inflammatory Joint Diseases: A Vigibase(R) Study with Disproportionality Analysis.

HOME
>
論文・技術情報
>
Asthma Reporting with Anti-TNFalpha Drugs used in Inflammatory Joint Diseases: A Vigibase(R) Study with Disproportionality Analysis.

アブストラクト	Large studies investigating asthma as a potential adverse event of anti-TNFalpha drugs are lacking. In our study, asthma was more likely to be reported with anti-TNFalpha drugs compared to biologics and small molecules in RA but exclusively with adalimumab.
ジャーナル名	Lung
Pubmed追加日	2026/3/27
投稿者	Nocenti, Matthias; Montastruc, Francois; Degboe, Yannick; Guilleminault, Laurent
組織名	Department of Respiratory Medicine, Faculty of Medicine, Toulouse University;Hospital, Toulouse, France.;Department of Medical and Clinical Pharmacology, Faculty of Medicine, Toulouse;University Hospital, Toulouse, France.;Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Equipe PEPSS;Pharmacologie En Population Cohortes et Biobanques, Toulouse, France.;Rheumatology Department, Pierre-Paul Riquet Hospital, University, Paul Sabatier;Toulouse III, Toulouse, France.;Univ Toulouse, INSERM, CNRS, Infinity - Toulouse Institute for Infectious and;Inflammatory Diseases, Toulouse, France.;Hospital, Toulouse, France. guilleminault.l@chu-toulouse.fr.;Inflammatory Diseases, Toulouse, France. guilleminault.l@chu-toulouse.fr.;CRISALIS network/F-CRIN Inserm, 31059, Toulouse, France.;guilleminault.l@chu-toulouse.fr.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/41893999/